Summary
Vertex Pharmaceuticals announced on February 21, 2019, the appointment of Lloyd Carney as a new member of its Board of Directors. This appointment effectively increases the size of the board from nine to ten members and is expected to strengthen the board's expertise, particularly with Mr. Carney's expected addition to the Audit and Finance Committee. Mr. Carney brings a wealth of experience in leadership roles within the technology sector, having served as CEO of prominent companies such as Brocade Communications Systems, Xsigo Systems, and Micromuse Inc., all of which were subject to significant acquisitions. His current and past board memberships, including at Visa Inc. and Nuance Communications, further underscore his valuable insights into corporate governance and strategic oversight. This appointment is a strategic move by Vertex to enhance its board's capabilities as it continues its growth trajectory.
Key Highlights
- 1Lloyd Carney appointed as a new Director to the Board, effective February 21, 2019.
- 2Board size increased from nine to ten members.
- 3Mr. Carney is expected to join the Audit and Finance Committee.
- 4Mr. Carney has extensive CEO experience in the technology sector, including leadership roles at Brocade, Xsigo Systems, and Micromuse.
- 5He currently serves on the boards of Visa Inc. and Nuance Communications, Inc.
- 6Mr. Carney received a $400,000 restricted stock unit award upon joining the board, vesting in February 2019.